Jennifer Diamond
Concepts (272)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Triple Negative Breast Neoplasms | 11 | 2021 | 155 | 5.090 |
Why?
| Breast Neoplasms | 17 | 2021 | 2006 | 3.430 |
Why?
| Pyrimidines | 9 | 2021 | 414 | 2.800 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2022 | 1430 | 2.470 |
Why?
| Antineoplastic Agents | 20 | 2020 | 2062 | 2.460 |
Why?
| Neoplasms | 14 | 2022 | 2163 | 1.960 |
Why?
| Immunoconjugates | 5 | 2021 | 87 | 1.960 |
Why?
| Receptor, ErbB-2 | 8 | 2021 | 333 | 1.920 |
Why?
| Paclitaxel | 6 | 2022 | 209 | 1.880 |
Why?
| Pyrazoles | 6 | 2021 | 405 | 1.610 |
Why?
| Camptothecin | 7 | 2022 | 97 | 1.590 |
Why?
| Protein Kinase Inhibitors | 9 | 2022 | 889 | 1.560 |
Why?
| Quinoxalines | 2 | 2020 | 71 | 1.530 |
Why?
| Ovarian Neoplasms | 4 | 2020 | 386 | 1.500 |
Why?
| Azepines | 3 | 2020 | 80 | 1.470 |
Why?
| Piperazines | 3 | 2020 | 330 | 1.470 |
Why?
| Antibodies, Monoclonal, Humanized | 8 | 2021 | 667 | 1.350 |
Why?
| Neutropenia | 4 | 2022 | 134 | 1.060 |
Why?
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 1216 | 0.920 |
Why?
| beta Catenin | 2 | 2020 | 229 | 0.880 |
Why?
| Breast Neoplasms, Male | 2 | 2018 | 31 | 0.870 |
Why?
| Xenograft Model Antitumor Assays | 10 | 2021 | 786 | 0.850 |
Why?
| Cancer Care Facilities | 1 | 2020 | 33 | 0.810 |
Why?
| Maximum Tolerated Dose | 9 | 2022 | 190 | 0.810 |
Why?
| Benzoxazoles | 1 | 2020 | 23 | 0.810 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2022 | 204 | 0.790 |
Why?
| Carcinoma, Lobular | 2 | 2018 | 59 | 0.790 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 117 | 0.780 |
Why?
| eIF-2 Kinase | 1 | 2019 | 30 | 0.770 |
Why?
| Cyclin-Dependent Kinase 4 | 1 | 2018 | 37 | 0.720 |
Why?
| Cyclin-Dependent Kinase 6 | 1 | 2018 | 37 | 0.710 |
Why?
| Wnt Signaling Pathway | 1 | 2019 | 138 | 0.680 |
Why?
| Drug Resistance, Neoplasm | 4 | 2020 | 707 | 0.670 |
Why?
| Aurora Kinase A | 4 | 2020 | 58 | 0.660 |
Why?
| Female | 41 | 2021 | 64422 | 0.660 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2018 | 94 | 0.660 |
Why?
| Tumor Microenvironment | 1 | 2020 | 423 | 0.650 |
Why?
| Pyrazines | 2 | 2018 | 81 | 0.640 |
Why?
| Colonic Neoplasms | 1 | 2018 | 224 | 0.610 |
Why?
| Neoadjuvant Therapy | 1 | 2018 | 311 | 0.590 |
Why?
| Humans | 51 | 2022 | 119016 | 0.580 |
Why?
| Angiopoietin-1 | 1 | 2015 | 9 | 0.570 |
Why?
| Angiopoietin-2 | 1 | 2015 | 14 | 0.570 |
Why?
| Aged | 20 | 2021 | 20607 | 0.530 |
Why?
| Tumor Suppressor Protein p53 | 3 | 2016 | 475 | 0.530 |
Why?
| Uterine Cervical Neoplasms | 1 | 2017 | 213 | 0.520 |
Why?
| Middle Aged | 23 | 2021 | 29243 | 0.490 |
Why?
| Cell Line, Tumor | 8 | 2022 | 2933 | 0.480 |
Why?
| Tumor Suppressor Proteins | 1 | 2015 | 286 | 0.480 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2013 | 74 | 0.470 |
Why?
| Point Mutation | 1 | 2013 | 239 | 0.450 |
Why?
| Cell Proliferation | 8 | 2020 | 2382 | 0.450 |
Why?
| Adult | 23 | 2022 | 32799 | 0.450 |
Why?
| Treatment Outcome | 12 | 2022 | 9492 | 0.450 |
Why?
| Dose-Response Relationship, Drug | 6 | 2022 | 2197 | 0.450 |
Why?
| Recombinant Fusion Proteins | 1 | 2015 | 701 | 0.450 |
Why?
| Triazoles | 1 | 2013 | 141 | 0.450 |
Why?
| Angiogenesis Inhibitors | 3 | 2018 | 221 | 0.430 |
Why?
| Carcinoma, Renal Cell | 1 | 2013 | 176 | 0.420 |
Why?
| Mitochondria | 1 | 2017 | 834 | 0.410 |
Why?
| Neoplasm Recurrence, Local | 4 | 2021 | 844 | 0.410 |
Why?
| Clinical Trials, Phase I as Topic | 2 | 2020 | 55 | 0.410 |
Why?
| Colorectal Neoplasms | 4 | 2022 | 636 | 0.410 |
Why?
| Trastuzumab | 3 | 2021 | 106 | 0.410 |
Why?
| Genes, BRCA2 | 1 | 2009 | 24 | 0.390 |
Why?
| Genes, BRCA1 | 1 | 2009 | 29 | 0.390 |
Why?
| Neoplasm Metastasis | 4 | 2020 | 617 | 0.390 |
Why?
| Nuclear Proteins | 1 | 2015 | 640 | 0.390 |
Why?
| Biomarkers, Tumor | 2 | 2014 | 1080 | 0.380 |
Why?
| BRCA2 Protein | 1 | 2009 | 43 | 0.370 |
Why?
| Mice, Nude | 5 | 2020 | 704 | 0.370 |
Why?
| Pregnancy Complications, Neoplastic | 1 | 2009 | 53 | 0.370 |
Why?
| Molecular Targeted Therapy | 3 | 2019 | 382 | 0.360 |
Why?
| Aged, 80 and over | 8 | 2020 | 6913 | 0.360 |
Why?
| Kidney Neoplasms | 1 | 2013 | 336 | 0.360 |
Why?
| Chemotherapy, Adjuvant | 2 | 2021 | 336 | 0.360 |
Why?
| Neoplasm Staging | 5 | 2021 | 1248 | 0.360 |
Why?
| Thrombophilia | 1 | 2009 | 76 | 0.360 |
Why?
| Quinolines | 2 | 2021 | 141 | 0.350 |
Why?
| Aromatase Inhibitors | 2 | 2018 | 54 | 0.350 |
Why?
| Receptors, Progesterone | 2 | 2021 | 339 | 0.330 |
Why?
| DNA-Binding Proteins | 1 | 2015 | 1432 | 0.320 |
Why?
| Antibodies, Monoclonal | 3 | 2020 | 1325 | 0.320 |
Why?
| Receptors, Estrogen | 2 | 2021 | 403 | 0.310 |
Why?
| Mice | 9 | 2021 | 15850 | 0.310 |
Why?
| Antineoplastic Agents, Immunological | 2 | 2019 | 163 | 0.310 |
Why?
| Apoptosis | 6 | 2022 | 2639 | 0.300 |
Why?
| Models, Biological | 1 | 2014 | 1814 | 0.290 |
Why?
| Liver Neoplasms | 1 | 2009 | 467 | 0.280 |
Why?
| Cyclophosphamide | 2 | 2018 | 237 | 0.260 |
Why?
| Lung Neoplasms | 1 | 2017 | 2246 | 0.250 |
Why?
| Radiosurgery | 2 | 2019 | 320 | 0.240 |
Why?
| Doxorubicin | 2 | 2018 | 316 | 0.240 |
Why?
| Cyclin-Dependent Kinase 9 | 1 | 2022 | 10 | 0.230 |
Why?
| Histone Deacetylase 1 | 1 | 2022 | 19 | 0.230 |
Why?
| Histones | 2 | 2022 | 548 | 0.230 |
Why?
| Biopsy | 2 | 2018 | 1076 | 0.230 |
Why?
| Fluorouracil | 1 | 2022 | 154 | 0.230 |
Why?
| Aurora Kinases | 2 | 2012 | 34 | 0.230 |
Why?
| G2 Phase Cell Cycle Checkpoints | 3 | 2022 | 40 | 0.230 |
Why?
| Disease Progression | 4 | 2019 | 2524 | 0.220 |
Why?
| Topoisomerase I Inhibitors | 2 | 2022 | 16 | 0.220 |
Why?
| Anthracyclines | 1 | 2021 | 34 | 0.220 |
Why?
| Administration, Oral | 3 | 2022 | 808 | 0.220 |
Why?
| Animals | 10 | 2021 | 35392 | 0.220 |
Why?
| Taxoids | 1 | 2021 | 94 | 0.220 |
Why?
| Acetylation | 1 | 2022 | 227 | 0.210 |
Why?
| Biliary Tract Neoplasms | 1 | 2021 | 21 | 0.210 |
Why?
| Androstadienes | 1 | 2021 | 105 | 0.210 |
Why?
| Carboplatin | 1 | 2021 | 143 | 0.200 |
Why?
| Diarrhea | 2 | 2019 | 181 | 0.200 |
Why?
| Heterografts | 1 | 2021 | 131 | 0.200 |
Why?
| Necrosis | 2 | 2019 | 231 | 0.200 |
Why?
| Male | 14 | 2021 | 61786 | 0.200 |
Why?
| Hospitals, University | 1 | 2021 | 195 | 0.200 |
Why?
| Fatigue | 2 | 2022 | 313 | 0.200 |
Why?
| Drug Administration Schedule | 3 | 2017 | 813 | 0.200 |
Why?
| Histone Deacetylases | 1 | 2022 | 210 | 0.200 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 55 | 0.200 |
Why?
| Benzodiazepines | 1 | 2021 | 116 | 0.200 |
Why?
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2019 | 25 | 0.190 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 102 | 0.190 |
Why?
| Medicare | 2 | 2021 | 698 | 0.190 |
Why?
| Immune System | 1 | 2021 | 202 | 0.190 |
Why?
| Kaplan-Meier Estimate | 1 | 2021 | 904 | 0.180 |
Why?
| Albumins | 1 | 2019 | 101 | 0.180 |
Why?
| Aquaporin 4 | 1 | 2019 | 72 | 0.180 |
Why?
| Maintenance Chemotherapy | 1 | 2018 | 25 | 0.180 |
Why?
| Antibodies, Bispecific | 1 | 2018 | 29 | 0.180 |
Why?
| Tumor Cells, Cultured | 1 | 2020 | 1008 | 0.180 |
Why?
| Nausea | 1 | 2018 | 116 | 0.170 |
Why?
| Aminopyridines | 1 | 2018 | 91 | 0.170 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2018 | 531 | 0.170 |
Why?
| Mastectomy | 1 | 2018 | 117 | 0.170 |
Why?
| Breast | 1 | 2018 | 151 | 0.170 |
Why?
| Benzimidazoles | 1 | 2018 | 146 | 0.160 |
Why?
| Topotecan | 1 | 2017 | 13 | 0.160 |
Why?
| Mice, Inbred BALB C | 1 | 2020 | 1328 | 0.160 |
Why?
| Purines | 1 | 2018 | 167 | 0.160 |
Why?
| Drug Therapy, Combination | 1 | 2020 | 1018 | 0.160 |
Why?
| Radiotherapy, Adjuvant | 1 | 2018 | 196 | 0.160 |
Why?
| Isoflavones | 1 | 2017 | 26 | 0.160 |
Why?
| Calcium-Binding Proteins | 1 | 2018 | 222 | 0.160 |
Why?
| Carbolines | 1 | 2017 | 34 | 0.160 |
Why?
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 15 | 0.160 |
Why?
| Disease Models, Animal | 2 | 2021 | 3894 | 0.160 |
Why?
| Imidazoles | 1 | 2018 | 264 | 0.160 |
Why?
| Inhibitory Concentration 50 | 2 | 2016 | 83 | 0.160 |
Why?
| Immunotherapy | 1 | 2021 | 478 | 0.160 |
Why?
| Nanoparticles | 1 | 2021 | 336 | 0.160 |
Why?
| Survival Analysis | 1 | 2020 | 1420 | 0.150 |
Why?
| Insulin-Like Growth Factor I | 1 | 2018 | 293 | 0.150 |
Why?
| Neoplasms, Radiation-Induced | 1 | 2016 | 76 | 0.150 |
Why?
| Neoplasms, Second Primary | 1 | 2016 | 75 | 0.150 |
Why?
| GPI-Linked Proteins | 1 | 2016 | 56 | 0.150 |
Why?
| Hypertension | 2 | 2018 | 1220 | 0.150 |
Why?
| Cell Survival | 1 | 2019 | 1137 | 0.150 |
Why?
| Retrospective Studies | 3 | 2021 | 12249 | 0.140 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 392 | 0.140 |
Why?
| Tumor Protein p73 | 1 | 2015 | 17 | 0.140 |
Why?
| Antibodies, Neoplasm | 1 | 2015 | 32 | 0.140 |
Why?
| Hodgkin Disease | 1 | 2016 | 117 | 0.140 |
Why?
| Risk Reduction Behavior | 1 | 2016 | 221 | 0.140 |
Why?
| Phosphorylation | 1 | 2019 | 1754 | 0.130 |
Why?
| Maytansine | 1 | 2014 | 14 | 0.130 |
Why?
| Pyridines | 1 | 2018 | 501 | 0.130 |
Why?
| Demography | 1 | 2015 | 292 | 0.130 |
Why?
| Brain Edema | 1 | 2014 | 66 | 0.130 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2019 | 1222 | 0.130 |
Why?
| Drug Interactions | 1 | 2015 | 401 | 0.130 |
Why?
| Survival Rate | 2 | 2019 | 1874 | 0.120 |
Why?
| Threonine | 1 | 2013 | 52 | 0.120 |
Why?
| Protein Kinases | 1 | 2015 | 336 | 0.120 |
Why?
| Sulfones | 1 | 2014 | 105 | 0.120 |
Why?
| Analgesics, Opioid | 1 | 2021 | 780 | 0.120 |
Why?
| Glycine | 1 | 2014 | 167 | 0.120 |
Why?
| Tumor Stem Cell Assay | 1 | 2012 | 39 | 0.120 |
Why?
| Drug Evaluation, Preclinical | 1 | 2013 | 198 | 0.120 |
Why?
| Methionine | 1 | 2013 | 158 | 0.120 |
Why?
| Heterozygote | 1 | 2013 | 257 | 0.120 |
Why?
| Drug Design | 1 | 2013 | 172 | 0.120 |
Why?
| Computational Biology | 1 | 2015 | 489 | 0.110 |
Why?
| Treatment Failure | 1 | 2013 | 343 | 0.110 |
Why?
| Disease-Free Survival | 1 | 2014 | 692 | 0.110 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2013 | 343 | 0.110 |
Why?
| Time Factors | 2 | 2020 | 7099 | 0.110 |
Why?
| Cellular Senescence | 1 | 2012 | 147 | 0.110 |
Why?
| Neovascularization, Pathologic | 1 | 2013 | 296 | 0.110 |
Why?
| Carcinoma in Situ | 1 | 2011 | 47 | 0.110 |
Why?
| Cluster Analysis | 1 | 2012 | 472 | 0.110 |
Why?
| Cell Transformation, Neoplastic | 1 | 2013 | 339 | 0.100 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 88 | 0.100 |
Why?
| Risk Assessment | 1 | 2020 | 3250 | 0.100 |
Why?
| Brain Neoplasms | 2 | 2019 | 1000 | 0.100 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 282 | 0.100 |
Why?
| Mutation | 2 | 2012 | 3468 | 0.100 |
Why?
| United States | 3 | 2021 | 12886 | 0.100 |
Why?
| Colorado | 1 | 2020 | 4577 | 0.100 |
Why?
| Sequence Analysis, DNA | 1 | 2013 | 741 | 0.100 |
Why?
| Tumor Burden | 1 | 2010 | 289 | 0.100 |
Why?
| Pregnancy Trimester, Second | 1 | 2009 | 81 | 0.090 |
Why?
| Mastectomy, Segmental | 1 | 2009 | 91 | 0.090 |
Why?
| Keratinocytes | 1 | 2010 | 244 | 0.090 |
Why?
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2009 | 64 | 0.090 |
Why?
| Pregnancy Trimester, First | 1 | 2009 | 124 | 0.090 |
Why?
| Clinical Trials as Topic | 2 | 2013 | 1022 | 0.090 |
Why?
| Lymph Node Excision | 1 | 2009 | 156 | 0.090 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2009 | 215 | 0.090 |
Why?
| Infusions, Intravenous | 2 | 2019 | 407 | 0.080 |
Why?
| Cell Adhesion Molecules | 2 | 2019 | 188 | 0.080 |
Why?
| Antigens, Neoplasm | 2 | 2019 | 232 | 0.080 |
Why?
| Risk Factors | 1 | 2020 | 9266 | 0.080 |
Why?
| Risk | 1 | 2009 | 956 | 0.080 |
Why?
| Prognosis | 2 | 2018 | 3592 | 0.080 |
Why?
| Gene Expression Profiling | 1 | 2012 | 1590 | 0.070 |
Why?
| Cell Cycle | 2 | 2018 | 594 | 0.070 |
Why?
| Combined Modality Therapy | 2 | 2019 | 1230 | 0.060 |
Why?
| Mesylates | 1 | 2022 | 6 | 0.060 |
Why?
| Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 63 | 0.060 |
Why?
| Signal Transduction | 2 | 2014 | 4919 | 0.060 |
Why?
| Chimerism | 1 | 2021 | 29 | 0.050 |
Why?
| Lymphoid Tissue | 1 | 2021 | 65 | 0.050 |
Why?
| Lymphocyte Subsets | 1 | 2021 | 84 | 0.050 |
Why?
| Liver | 1 | 2009 | 1873 | 0.050 |
Why?
| Mice, SCID | 1 | 2021 | 372 | 0.050 |
Why?
| SEER Program | 1 | 2021 | 208 | 0.050 |
Why?
| Mice, Inbred NOD | 1 | 2021 | 597 | 0.050 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2018 | 23 | 0.050 |
Why?
| Infant, Newborn | 1 | 2009 | 5203 | 0.040 |
Why?
| Tissue Distribution | 1 | 2018 | 366 | 0.040 |
Why?
| Anemia | 1 | 2019 | 168 | 0.040 |
Why?
| Pregnancy | 1 | 2009 | 5546 | 0.040 |
Why?
| Retreatment | 1 | 2016 | 70 | 0.040 |
Why?
| Cetuximab | 1 | 2016 | 98 | 0.040 |
Why?
| Platinum | 1 | 2016 | 38 | 0.040 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 122 | 0.040 |
Why?
| Neoplasm Transplantation | 1 | 2016 | 263 | 0.040 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2016 | 193 | 0.040 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 572 | 0.040 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 238 | 0.040 |
Why?
| History, Ancient | 1 | 2015 | 45 | 0.040 |
Why?
| Databases, Genetic | 1 | 2015 | 173 | 0.030 |
Why?
| Biomarkers | 2 | 2016 | 3583 | 0.030 |
Why?
| Opioid-Related Disorders | 1 | 2021 | 360 | 0.030 |
Why?
| DNA Damage | 1 | 2017 | 373 | 0.030 |
Why?
| Mice, Knockout | 1 | 2021 | 2862 | 0.030 |
Why?
| Phenotype | 1 | 2021 | 2938 | 0.030 |
Why?
| Drug Combinations | 1 | 2013 | 309 | 0.030 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 233 | 0.030 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 407 | 0.030 |
Why?
| Immunohistochemistry | 1 | 2016 | 1802 | 0.030 |
Why?
| Biopsy, Needle | 1 | 2011 | 201 | 0.030 |
Why?
| Cohort Studies | 1 | 2021 | 5129 | 0.030 |
Why?
| HT29 Cells | 1 | 2010 | 38 | 0.030 |
Why?
| Transcription, Genetic | 1 | 2017 | 1472 | 0.020 |
Why?
| Ki-67 Antigen | 1 | 2010 | 110 | 0.020 |
Why?
| Cell Cycle Proteins | 1 | 2014 | 573 | 0.020 |
Why?
| ErbB Receptors | 1 | 2013 | 575 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2014 | 941 | 0.020 |
Why?
| Capillary Permeability | 1 | 2010 | 163 | 0.020 |
Why?
| Protein-Tyrosine Kinases | 1 | 2013 | 456 | 0.020 |
Why?
| Proto-Oncogene Proteins | 1 | 2014 | 726 | 0.020 |
Why?
| Patient Selection | 1 | 2013 | 710 | 0.020 |
Why?
| Patient Satisfaction | 1 | 2013 | 621 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2018 | 5000 | 0.020 |
Why?
| Membrane Proteins | 1 | 2015 | 1110 | 0.020 |
Why?
| Positron-Emission Tomography | 1 | 2010 | 309 | 0.020 |
Why?
| Algorithms | 1 | 2015 | 1552 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2019 | 3266 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2016 | 2431 | 0.020 |
Why?
| Brain | 1 | 2014 | 2787 | 0.010 |
Why?
| Young Adult | 1 | 2014 | 11181 | 0.010 |
Why?
|
|
Diamond's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|